Long-Term Repigmentation Outcomes and Real-World Use of Ruxolitinib Cream

In this episode, Long-Term Repigmentation Outcomes and Real-World Use of Ruxolitinib Cream, Dr. Desai explores the following questions:

What repigmentation outcomes were reported in the pooled 104-week analysis of the TRuE-V program?

Which patients are you using ruxolitinib in and what has access been like?

In the pooled 104-week analysis of the TRuE-V program, repigmentation outcomes continued to improve over time, with a growing proportion of patients achieving F-VASI75 and even F-VASI90, reflecting durable and progressive facial repigmentation. These long-term data reinforce the importance of sustained therapy, as many patients who did not respond early went on to achieve clinically meaningful improvement with continued use. In practice, ruxolitinib cream is most commonly used in patients with nonsegmental vitiligo, particularly those with facial involvement or limited body surface area where topical therapy is feasible. Access in the real world can be variable, often influenced by insurance coverage, prior authorization requirements, and cost considerations, which may impact treatment initiation and persistence.

The next episode in this series, Emerging Role of Oral JAK Inhibition in Vitiligo Management, focuses on clinical evidence supporting oral upadacitinib in vitiligo, which is evolving, with early studies demonstrating its ability to modulate key inflammatory pathways and promote repigmentation, supporting its investigation as a systemic treatment option. If FDA-approved, upadacitinib would likely be considered for patients with more extensive or refractory disease, while ruxolitinib cream remains well suited for localized involvement, with oral therapy offering broader systemic control but carrying greater safety considerations compared with the favorable tolerability and targeted application of topical treatment.